Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases

Introduction: Our previous studies showed elevated levels of Semaphorin3a (Sema3A) in the urine of patients with urothelial cancer compared to healthy patients. The aim of this study was to analyze the extent of Sema3A expression in normal and malignant urothelial tissue using immune-staining microscopic and morphometric analysis. Materials and Methods: Fifty-seven paraffin-embedded bladder samples were retrieved from our pathology archive and analyzed: 14 samples of normal urothelium, 21 samples containing low-grade urothelial carcinoma, 13 samples of patients with high-grade urothelial carcinoma, 7 samples containing muscle invasive urothelial carcinoma, and 2 samples with pure urothelial carcinoma in situ. All samples were immunostained with anti Sema3A antibodies. The area of tissue stained with Sema3A and its intensity were analyzed using computerized morphometry and compared between the samples’ groups. Results: In normal bladder tissue, very light Sema3A staining was demonstrated on the mucosal basal layer and completely disappeared on the apical layer. In low-grade tumor samples, cells in the basal layer of the mucosa were also lightly stained with Sema3A, but Seama3A expression intensified upon moving apically, reaching its highest level on apical cells exfoliating to the urine. In high grade urothelial tumors, Seama3A staining was intense in the entire thickness of the mucosa. In samples containing carcinoma in situ, staining intensity was high and homogenous in all the neoplastic cells. Conclusions: Sema3A may be serve as a potential non-invasive marker of urothelial cancer.

Download Full-text

Urine cytology findings in patients with biopsy‐confirmed urothelial carcinoma in situ with plasmacytoid features

Cancer Cytopathology ◽

10.1002/cncy.22445 ◽

2021 ◽

Author(s):

Meredith M. Nichols ◽

Jordan P. Reynolds ◽

Jesse K. McKenney ◽

Marlo M. Nicolas ◽

Patrick J. McIntire ◽

...

Keyword(s):

Urothelial Carcinoma ◽

Carcinoma In Situ ◽

Urine Cytology

Download Full-text

Pagetoid Bowen Disease

Archives of Pathology & Laboratory Medicine ◽

10.5858/2000-124-0427-pbdaro ◽

2000 ◽

Vol 124 (3) ◽

pp. 427-430 ◽

Cited By ~ 9

Author(s):

John D. Williamson ◽

Maria I. Colome ◽

Aysegul Sahin ◽

Alberto G. Ayala ◽

L. Jeffrey Medeiros

Keyword(s):

Differential Diagnosis ◽

Carcinoma In Situ ◽

Clinical Evidence ◽

Malignant Neoplasm ◽

The Other ◽

Paget Disease ◽

Melanoma In Situ ◽

Bowen Disease ◽

Hmb 45

Abstract Bowen disease is a variant of squamous cell carcinoma in situ. In some cases a pagetoid growth pattern can be observed with cytologically atypical clear cells arranged singly and in nests. The differential diagnosis of pagetoid Bowen disease includes primarily Paget disease and malignant melanoma in situ, as well as other less common entities. Two cases of pagetoid Bowen disease are described, one in a 65-year-old man with a thigh lesion and the other in a 25-year-old man with a lesion in the penile/scrotal region. Neither patient had clinical evidence of an internal malignant neoplasm. In both cases, the neoplastic cells were positive for cytokeratin (CK) 7 and CK 19 and were negative for CK 18, CK 20, carcinoembryonic antigen, GCDFP-15, c-erbB2, S100, and HMB-45. In aggregate, these findings support the diagnosis of pagetoid Bowen disease. Previously, others have shown that CK 7 is an almost invariable marker of Paget disease. Thus, we report these two cases to illustrate that CK 7 can be expressed by pagetoid Bowen disease and should not be a cause of confusion in the differential diagnosis.

Download Full-text

Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast

SAGE Open Medicine ◽

10.1177/2050312118811542 ◽

2018 ◽

Vol 6 ◽

pp. 205031211881154 ◽

Cited By ~ 3

Author(s):

Ichiro Maeda ◽

Shinya Tajima ◽

Yoshihide Kanemaki ◽

Koichiro Tsugawa ◽

Masayuki Takagi

Keyword(s):

Differential Diagnosis ◽

Papillary Carcinoma ◽

Carcinoma In Situ ◽

Immunohistochemical Staining ◽

Immunohistochemical Analysis ◽

Intraductal Papilloma ◽

Solid Papillary Carcinoma ◽

Usual Ductal Hyperplasia ◽

Ductal Hyperplasia

Objectives: The aim of this study was to use immunohistochemistry to differentiate solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia (IPUDH). Three types of high-molecular-weight cytokeratins (CKs) – CK5/6, CK14, and CK34betaE12 – were targeted. Methods: We studied 17 patients with solid papillary carcinoma in situ and 18 patients with IPUDH diagnosed by at least two pathologists. Immunohistochemical analyses used antibodies to CK5/6, CK14, and CK34betaE12 to make the differential diagnosis of solid papillary carcinoma in situ versus IPUDH. Immunohistochemical staining was scored as 0–5 using Allred score. Results: Immunohistochemistry with CK5/6 and CK14 antibodies produced scores of 0–3 in all patients with solid papillary carcinoma in situ and 2–5 in all patients with IPUDH. Immunohistochemical staining with CK34betaE12 antibody produced scores of 1–3 in all patients with solid papillary carcinoma and 3–5 in all patients with IPUDH. In tissues from patients with IPUDH, significantly more cells were stained with CK34betaE12 than CK5/6 ( p < 0.05) or CK14 ( p < 0.05). Conclusion: The immunoreactivity of CK5/6, CK14, and CK34betaE12 antibodies was useful to differentiate solid papillary carcinoma in situ from IPUDH. CK34betaE12 is especially useful for distinguishing solid papillary carcinoma from IPUDH.

Download Full-text